secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-009982
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Therapeutics reports Q4 2024 net loss $10.9M; cash $60.2M; ALXN1840 NDA planned early 2026
--------------------------------------------------------------------------------

- Q4 2024 net loss $10.9M ($2.23/share) vs $1.8M ($0.60/share) in Q4 2023.
- FY2024 net loss $15.6M ($4.11/share) vs $8.4M ($3.04/share) in FY2023; R&D expenses rose to $13.0M from $5.6M.
- Cash and short-term investments $60.2M at Dec 31, 2024; expects runway through Dec 31, 2026.
- Plan to submit NDA for ALXN1840 (Wilson disease) to FDA in early 2026.
- Raised net proceeds ~$55M from Q4 2024 financings; MNPR-101-Lu Phase 1a dosed first patient in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/0001437749-25-009982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/mnpr20250326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer